Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylethylamine and schizophrenia

R L O'Reilly1, B A Davis

  • 1Department of Psychiatry, University of Western Ontario, London, Canada.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Genomics Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos.

Journal of equine veterinary science·2026
Same author

Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells.

Nature communications·2023
Same author

Post-zygotic genomic changes in glutamate and dopamine pathway genes may explain discordance of monozygotic twins for schizophrenia.

Clinical and translational medicine·2017
Same author

Dopaminergic and behavioural changes in a loss-of-imprinting model of Cdkn1c.

Genes, brain, and behavior·2017
Same author

Integration of DNA sequence and DNA methylation changes in monozygotic twin pairs discordant for schizophrenia.

Schizophrenia research·2015
Same author

Analysis of copper in brain by the mass-spectrometric integrated-ioncurrent procedure.

Neurochemical research·2013
Same journal

Mapping intrinsic neural timescale alterations in major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Beyond gray matter: unveiling the critical role of white matter in Alzheimer's disease.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Chronic pain and stress: Transdiagnostic meta-analytic evidence of convergent network signature with PTSD.

Progress in neuro-psychopharmacology & biological psychiatry·2026
See all related articles

Phenylethylamine (PEA) may contribute to schizophrenia development, similar to amphetamines. While urinary PEA levels are often high in patients, findings in other bodily fluids are inconsistent, potentially due to medication effects.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Biochemistry

Background:

  • Phenylethylamine (PEA) is structurally and physiologically similar to amphetamines, which can induce psychosis.
  • Schizophrenia is a complex psychiatric disorder with debated etiological factors.
  • The role of endogenous substances like PEA in psychosis is an area of ongoing research.

Purpose of the Study:

  • To review the evidence linking phenylethylamine (PEA) to the etiology of schizophrenia.
  • To explore potential mechanisms by which PEA might influence schizophrenia.
  • To identify confounding factors in current research on PEA and schizophrenia.

Main Methods:

  • Literature review of studies investigating PEA levels in schizophrenia patients.
  • Analysis of biochemical and physiological similarities between PEA and amphetamines.

Related Experiment Videos

  • Examination of confounding variables, particularly neuroleptic medication, in clinical studies.

    • Main Results:

    • Inconsistent findings exist regarding PEA and its metabolite phenylacetic acid levels in various body fluids of schizophrenic patients.
    • High urinary PEA excretion has been reported in some schizophrenic individuals.
    • Neuroleptic medication significantly confounds the interpretation of clinical studies.

    Conclusions:

    • The evidence for PEA's direct role in schizophrenia etiology remains inconclusive.
    • PEA may influence schizophrenia by amplifying dopamine responses.
    • Further research controlling for medication effects is needed to clarify PEA's role.